Brief: OSE Immunotherapeutics To Continue Clinical Development In Ulcerative Colitis, Transfers Full Rights To Lusvertikimab

Ose Immunotherapeutics SA

12/05/2023 17:17

May 12 (Reuters) - OSE Immunotherapeutics SA  OSE.PA :
    * TO CONTINUE CLINICAL DEVELOPMENT IN ULCERATIVE COLITIS
WITH FULL
RIGHTS TO LUSVERTIKIMAB
    * RETAINS GLOBAL AND FULL RIGHTS ON LUSVERTIKIMAB
    * OSE IMMUNOTHERAPEUTICS AND SERVIER DECIDED TO MUTUALLY
TERMINATE
THEIR AGREEMENT BASED ON OSE IMMUNOTHERAPEUTICS’ STRATEGIC
COMMITMENT IN ULCERATIVE COLITIS AND FOLLOWING SERVIER’S
PRIORITY PORTFOLIO REVIEW AFTER THE NEGATIVE RESULTS ON THEIR
EXPLORATORY PHASE 2A CLINICAL STUDY IN THE PRIMARY SJÖGREN
SYNDROME (SPONSORED BY SERVIER)

Source text for Eikon:  ID:nBw74pgCGa 
Further company coverage:  OSE.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))